Chemokines in tumor immunotherapy

Frontiers in Bioscience

Volumn 11, Issue 1 P.889-1198, 2006, Pages 1024-1030

  Flanagan, Kenneth ^a   Kaufman, Howard L ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Cancer; Chemokines; Immunotherapy; Neoplaia; Review; Therapeutics; Treatment; Tumor

Indexed keywords

EID: 32844468663     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1860     Document Type: Review

References (67)

1. Matzinger, P.: An innate sense of danger. Ann N Y Acad Sci 961:341 (2002)
2. Viret, C., & C. A. Janeway, Jr.: MHC and T cell development. Rev Immunogenet 1:91 (1999)
3. Cyster, J. G.: Leukocyte migration: scent of the T zone. Curr Biol 10:R30 (2000)
4. Mackay, C. R.: Chemokines: immunology's high impact factors. Nat Immunol 2:95 (2001)
5. Sherry, B., & A. Cerami: Small cytokine superfamily. Curr Opin Immunol 3:56 (1991)
6. Baggiolini, M.: Chemokines in pathology and medicine. J Intern Med 250:91 (2001)
7. Devalaraja, M. N., and A. Richmond: Multiple chemotactic factors: fine control or redundancy? Trends Pharmacol Sci 20:151 (1999)
8. Mantovani, A.: The chemokine system: redundancy for robust outputs. Immunol Today 20:254 (1999)
9. Baggiolini, M., B. Dewald, & B. Moser: Human chemokines: an update. Annu Rev Immunol 15:675 (1997)
10. Kucik, D. F.: Rearrangement of integrins in avidity regulation by leukocytes. Immunol Res 26:199 (2002)
11. Alon, R., & S. Feigelson: From rolling to arrest on blood vessels: leukocyte tap dancing on endothelial integrin ligands and chemokines at sub-second contacts. Semin Immunol 14:93 (2002)
12. Laudanna, C., J. Y. Kim, G. Constantin, & E. Butcher: Rapid leukocyte integrin activation by chemokines. Immunol Rev 186:37 (2002)
13. Moser, B., & P. Loetscher: Lymphocyte traffic control by chemokines. Nat Immunol 2:123 (2001)
14. Dias, S., M. Choy, & S. Rafii: The role of CXC chemokines in the regulation of tumor angiogenesis. Cancer Invest 19:732 (2001)
15. Sallusto, F.: The role of chemokines and chemokine receptors in T cell priming and Th1/Th2-mediated responses. Haematologica 84 Suppl EHA-4:28 (1999)
16. Mori, S., H. Nakano, K. Aritomi, C. R. Wang, M. D. Gunn, & T. Kakiuchi: Mice lacking expression of the chemokines CCL21-ser and CCL19 (plt mice) demonstrate delayed but enhanced T cell immune responses. J Exp Med 193:207 (2001)
17. Murphy, P. M.: Viral exploitation and subversion of the immune system through chemokine mimicry. Nat Immunol 2:116 (2001)
18. Smith, G. L.: Vaccinia virus immune evasion. Immunol Lett 65:55 (1999)
19. Smith, V. P., & A. Alcami: Expression of secreted cytokine and chemokine inhibitors by ectromelia virus. J Virol 74:8460 (2000)
20. Seet, B. T., & G. McFadden: Viral chemokine-binding proteins. J Leukoc Biol 72:24 (2002)
21. van Berkel, V., J. Barrett, H. L. Tiffany, D. H. Fremont, P. M. Murphy, G. McFadden, S. H. Speck, & H. I. Virgin: Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J Virol 74:6741 (2000)
22. Boshoff, C., & R. A. Weiss: Kaposi's sarcoma-associated herpesvirus. Adv Cancer Res 75:57 (1998)
23. Farrell, H. E., M. A. Degli-Esposti, & N. J. Davis-Poynter: Cytomegalovirus evasion of natural killer cell responses. Immunol Rev 168:187 (1999)
24. Benomar, A., W. J. Ming, G. Taraboletti, P. Ghezzi, C. Balotta, G. J. Cianciolo, R. Snyderman, J. F. Dore, & A. Mantovani: Chemotactic factor and P15E-related chemotaxis inhibitor in human melanoma cell lines with different macrophage content and tumorigenicity in nude mice. J Immunol 138:2372 (1987)
25. Bottazzi, B., F. Colotta, A. Sica, N. Nobili, & A. Mantovani: A chemoattractant expressed in human sarcoma cells (tumor-derived chemotactic factor, TDCF) is identical to monocyte chemoattractant protein-1/monocyte chemotactic and activating factor (MCP-1/MCAF). Int J Cancer 45:795 (1990)
26. Flanagan, K., & H. L. Kaufinan: Chemokines and cancer. Cancer Invest 20:825 (2002)
27. Negus, R. P., G. W. Stamp, J. Hadley, & F. R. Balkwill: Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 150:1723 (1997)
28. Richmond, A., & H. G. Thomas: Purification of melanoma growth stimulatory activity. J Cell Physiol 129:375 (1986)
29. Lawson, D. H., H. G. Thomas, R. G. Roy, D. S. Gordon, R. K. Chawla, D. W. Nixon, & A. Richmond: Preparation of a monoclonal antibody to a melanoma growth-stimulatory activity released into serum-free culture medium by Hs0294 malignant melanoma cells. J Cell Biochem 34:169 (1987)
30. Schadendorf, D., A. Moller, B. Algermissen, M. Worm, M. Sticherling, & B. M. Czametzki: IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 151:2667 (1993)
31. Orlowski, R. Z., & A. S. Baldwin, Jr.: NF-kappaB as a therapeutic target in cancer. Trends Mol Med 8:385 (2002)
32. Liou, H. C.: Regulation of the immune system by NF-kappaB and IkappaB. J Biochem Mol Biol 35:537 (2002)
33. Balkwill, F.: Chemokine biology in cancer. Semin Immunol 15:49 (2003)
34. Vanderkerken, K., I. Van de Broek, D. L. Eizirik, E. Van Valckenborgh, K. Asosingh, I. Van Riet, & B. Van Camp.: Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells. Clin Exp Metastasis 19:87 (2002)
35. Takanami, I.: Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer 105:186 (2003)
36. Youngs, S. J., S. A. Ali, D. D. Taub, & R. C. Rees: Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer 71:257 (1997)
37. Fernandis, A. Z., A. Prasad, H. Band, R. Klosel, & R. K. Ganju: Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 23:157 (2004)
38. Loukinova, E., G. Dong, I. Enamorado-Ayalya, G. R. Thomas, Z. Chen, H. Schreiber, & C. Van Waes: Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene 19:3477 (2000)
39. Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, & R. D. Schreiber: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991 (2002)
40. Laning, J., H. Kawasaki, E. Tanaka, Y. Luo, & M. E. Dorf: Inhibition of in vivo tumor growth by the beta chemokine, TCA3. J Immunol 153:4625 (1994)
41. Mule, J. J., M. Custer, B. Averbook, J. C. Yang, J. S. Weber, D. V. Goeddel, S. A. Rosenberg, & T. J. Schall: RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther 7:1545 (1996)
42. Nakashima, E., A. Oya, Y. Kubota, N. Kanada, R. Matsushita, K. Takeda, F. Ichimura, K. Kuno, N. Mukaida, K. Hirose, I. Nakanishi, T. Ujiie, & K. Matsushima: A candidate for cancer gene therapy: MIP-1 alpha gene transfer to an adenocarcinoma cell line reduced tumorigenicity and induced protective immunity in immunocompetent mice. Pharm Res 13:1896 (1996)
43. Azenshtein, E., G. Luboshits, S. Shina, E. Neumark, D. Shahbazian, M. Weil, N. Wigler, I. Keydar, & A. Ben-Baruch: The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 62:1093 (2002)
44. Huang, S., R. K. Singh, K. Xie, M. Gutman, K. K. Berry, C. D. Bucana, I. J. Fidler, & M. Bar-Eli: Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol Immunother 39:231 (1994)
45. Huang, S., K. Xie, R. K. Singh, M. Gutman, and M. Bar-Eli: Suppression of tumor growth and metastasis of murine renal adenocarcinoma by syngeneic fibroblasts genetically engineered to secrete the JE/MCP-1 cytokine. J Interferon Cytokine Res 15:655 (1995)
46. Beutler, B., & E. T. Rietschel: Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 3:169 (2003)
47. Dilloo, D., K. Bacon, W. Holden, W. Zhong, S. Burdach, A. Zlotnik, & M. Brenner: Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 2:1090 (1996)
48. Kelner, G. S., J. Kennedy, K. B. Bacon, S. Kleyensteuber, D. A. Largaespada, N. A. Jenkins, N. G. Copeland, J. F. Bazan, K. W. Moore, & T. J. Schall: Lymphotactin: a cytokine that represents a new class of chemokine. Science 266:1395 (1994)
49. Narvaiza, I., G. Mazzolini, M. Barajas, M. Duarte, M. Zaratiegui, C. Qian, I. Melero, & J. Prieto: Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol 164:3112 (2000)
50. Kaufman, H. L., K. Cheung, Z. Haskall, H. Horig, C. Hesdorffer, D. Panicali, G. DeRaffele, & K. Spanknebel: Clinical protocol. Intra-Lesional rF-B7.1 versus rF-TRICOM vaccine in the treatment of metastatic cancer. Hum Gene Ther 14:803 (2003)
51. Belldegrun, A., C. L. Tso, A. Zisman, J. Naitoh, J. Said, A. J. Pantuck, A. Kinkel, J. deKernion, & R. Figlin.: Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther 12:883 (2001)
52. Caux, C., S. Ait-Yahia, K. Chemin, O. de Bouteiller, M. C. Dieu-Nosjean, B. Homey, C. Massacrier, B. Vanbervliet, A. Zlotnik, & A. Vicari: Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol 22:345 (2000)
53. Itano, A. A., & M. K. Jenkins. Antigen presentation to naive CD4 T cells in the lymph node. Nat Immunol 4:733 (2003)
54. Ochsenbein, A. F., S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. Hemmi, H. Hengartner, & R. M. Zinkernagel: Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411:1058 (2001)
55. Kirk, C. J., D. Hartigan-O'Connor, B. J. Nickoloff, J. S. Chamberlain, M. Giedlin, L. Aukerman, & J. J. Mule: T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 61:2062 (2001)
56. Braun, S. E., K. Chen, R. G. Foster, C. H. Kim, R. Hromas, M. H. Kaplan, H. E. Broxmeyer, & K. Cornetta: The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol 164:4025 (2000)
57. Kirk, C. J., D. Hartigan-O'Connor, & J. J. Mule: The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res 61:8794 (2001)
58. Khong, H. T., & N. P. Restifo: Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3:999 (2002)
59. Marsland B. J., P Battig, M Bauer, C Ruedl, U Lassing, RR Beerli, K Dietmeier, L Ivanova, T Pfister, L Vogt, H Nakano, C Nembrini, P Saudan, M Kopf, M. F. Bachmann: CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity 22: 293 (2005)
60. Flanagan, K., D. Moroziewicz, H. Kwak, H. Horig & H. L. Kaufinan: The lymphoid chemokine CCL21 costimulates naïve T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. Cell Immunol 231(1-2), 75 (2005)
61. Serra, P., A. Amrani, J. Yamanouchi, B. Han, S. Thiessen, T. Utsugi, J. Verdaguer, & P. Santamaria: CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. Immunity 19:877 (2003)
62. Sakaguchi, S.: Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101:455 (2000)
63. Shevach, E. M.: Control of T-cell responses by regulatory/suppressor T cells. Exp Dermatol 12:913 (2003)
64. Thornton, A. M., & E. M. Shevach: CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287 (1998)
65. Steitz, J., J. Bruck, J. Lenz, J. Knop, & T. Tuting: Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res 61:8643 (2001)
66. Ghiringhelli, F., N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin, C. Garrido, B. Chauffert, E. Solary, B. Bonnette, & F. Martin: CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34:336 (2004)
67. Fu, S., A. C. Yopp, X. Mao, D. Chen, N. Zhang, M. Mao, Y. Ding, & J. S. Bromberg: CD4+ CD25+ CD62+ T-regulatory cell subset has optimal suppressive and proliferative potential. Am J Transplant 4, 65 (2004)